Do you want to read an article? Please log in or register.
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma
Clin Pharmacol Ther.
Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L
doi: 10.1002/cpt.
Asthma
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Curr Med Res Opin.
Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X
doi: 10.1080/
RECOMMENDED
Asthma
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Lancet Respir Med.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators
doi: 10.1016/S2213-2600
Asthma
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
Ann Allergy Asthma Immunol.
Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M
doi: 10.1016/j.anai.2018.01.030.
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
Asthma
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma
Adv Ther.
Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E
doi: 10.1007/s12325-019-01191-2.
Asthma
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
Lancet Respir Med.
FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M
doi: 10.1016/
RECOMMENDED
Asthma
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Med.
Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, D'Amato M, De Ferrari L, Di Marco F, Imeri G, Di Bona D, Gilardenghi A, Guida G, Lombardi C, Milanese M, Nicolini A, Riccio AM, Rolla G, Santus P, Senna G, Passalacqua G
doi: 10.1016/j.rmed.2020.106080.
Asthma
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Lancet.
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators
doi: 10.1016/